TECENTRIQ conc perf 840 mg/14 ml flac 14 ml
7680661520029
CH-66152
L01FF05
07.16.1.
Reimbursement limitations:
TECENTR.01
2L du CPNPC
Tecentriq est indiqué en monothérapie pour le traitement des patients atteints d’un …
1 / 3
google
Details
- Product number
- 6615202
- CPT
- -
- Packaging group
- 1
- Unit
- Durchstechflasche(n)
- Composition
- atezolizumabum 840 mg, histidinum, acidum aceticum glaciale, saccharum, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 14 ml.
Articles (1)
Tecentriq 840 mg/14 ml, Konzentrat zur Herstellung einer Infusionslösung
Konzentrat
1
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
(N/A)
|
840.0 MG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
Authorization holder
Roche Pharma (Schweiz) AG
4058 Basel
Authorization information
- Swissmedic authorization number
- 66152
- Drug name
- Tecentriq, Konzentrat zur Herstellung einer Infusionslösung
- Galenic form
- KOINF
- ATC Code
- L01FF05
- Authorization status
- Z
- Dispensation category
- A
- First authorization
- 23/05/2017
- Authorization expiration date
- 31/12/9999
- IT number
- 07.16.1.
- Domain
- Human medicine
Packaging details
- Description (FR)
- TECENTRIQ conc perf 840 mg/14 ml flac 14 ml
- Description (DE)
- TECENTRIQ Inf Konz 840 mg/14 ml Durchstf 14 ml
- Market launch
- 21/05/2019
- Narcotic (BTM)
- No